TY - JOUR
T1 - Cannabinoids and autoimmune diseases
T2 - A systematic review
AU - Katchan, Valeria
AU - David, Paula
AU - Shoenfeld, Yehuda
N1 - Publisher Copyright:
© 2016 Elsevier B.V.
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Cannabinoids have shown to have a variety effects on body systems. Through CB1 and CB2 receptors, amongst other, they exert an effect by modulating neurotransmitter and cytokine release. Current research in the role of cannabinoids in the immune system shows that they possess immunosuppressive properties. They can inhibit proliferation of leucocytes, induce apoptosis of T cells and macrophages and reduce secretion of pro-inflammatory cytokines. In mice models, they are effective in reducing inflammation in arthritis, multiple sclerosis, have a positive effect on neuropathic pain and in type 1 diabetes mellitus. They are effective as treatment for fibromyalgia and have shown to have anti-fibrotic effect in scleroderma. Studies in human models are scarce and not conclusive and more research is required in this field. Cannabinoids can be therefore promising immunosuppressive and anti-fibrotic agents in the therapy of autoimmune disorders.
AB - Cannabinoids have shown to have a variety effects on body systems. Through CB1 and CB2 receptors, amongst other, they exert an effect by modulating neurotransmitter and cytokine release. Current research in the role of cannabinoids in the immune system shows that they possess immunosuppressive properties. They can inhibit proliferation of leucocytes, induce apoptosis of T cells and macrophages and reduce secretion of pro-inflammatory cytokines. In mice models, they are effective in reducing inflammation in arthritis, multiple sclerosis, have a positive effect on neuropathic pain and in type 1 diabetes mellitus. They are effective as treatment for fibromyalgia and have shown to have anti-fibrotic effect in scleroderma. Studies in human models are scarce and not conclusive and more research is required in this field. Cannabinoids can be therefore promising immunosuppressive and anti-fibrotic agents in the therapy of autoimmune disorders.
KW - Autoimmune diseases
KW - Cannabinoids
KW - Endocannabinoid system
KW - Fibromyalgia
KW - Immunosuppression
KW - Inflammatory bowel disease
KW - Multiple sclerosis
KW - Neuropathic pain
KW - Rheumatoid arthritis
KW - Scleroderma
KW - Tetrahydrocannabinol (THC)
KW - Type 1 Diabetes
UR - http://www.scopus.com/inward/record.url?scp=84963775522&partnerID=8YFLogxK
U2 - 10.1016/j.autrev.2016.02.008
DO - 10.1016/j.autrev.2016.02.008
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 26876387
AN - SCOPUS:84963775522
SN - 1568-9972
VL - 15
SP - 513
EP - 528
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
IS - 6
ER -